-

ADARx Pharmaceuticals to Present at the J.P. Morgan 42nd Annual Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced that Zhen Li, PhD, Co-Founder, President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9 at 4:30 p.m. PT in San Francisco, California.

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc. is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA delivery platforms and technology for silencing or editing target mRNA. ADARx has a growing pipeline of RNA therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiovascular, complement-mediated and central nervous system diseases. Follow ADARx on LinkedIn.

Contacts

Roselle Corbaley
(877) 232-7974
ir@adarx.com

Industry:

ADARX PHARMACEUTICALS, INC.

Details
Headquarters: San Diego, CA
CEO: Zhen Li
Employees: 50
Organization: PRI
Release Versions
English

Contacts

Roselle Corbaley
(877) 232-7974
ir@adarx.com

More News From ADARX PHARMACEUTICALS, INC.

ADARx Pharmaceuticals to Participate in the 44th Annual Cowen Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced that Zhen Li, PhD, Co-Founder, President and CEO, will host one-on-one investor meetings at the 44th Annual Cowen Healthcare Conference on Monday, March 4, 2024 in Boston, Massachusetts. About ADARx Pharmaceuticals ADARx Pharmaceuticals, Inc. is a clinical stage biotechnology company committed to turning cutting-edge science into li...

ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 Million Series C Financing

SAN DIEGO--(BUSINESS WIRE)--ADARx Pharmaceuticals, Inc. (“ADARx” or “the Company”), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the successful close of an oversubscribed $200 million Series C financing. The financing was led jointly by Bain Capital Life Sciences and TCGX and also included new investors Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price As...

ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324

SAN DIEGO--(BUSINESS WIRE)--ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks. “We are very excited to be advancing our first candidate that utilizes our proprietary PLR™ delivery platform and SPE™...
Back to Newsroom